Building a roadmap for developing combination therapies for Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 3, 2015, Pages 327-333

  Perry, Daniel ^a   Sperling, Reisa ^b   Katz, Russell ^c   Berry, Donald ^d   Dilts, David ^e   Hanna, Debra ^f   Salloway, Stephen ^g   Trojanowski, John Q ^h   Bountra, Chas ⁱ   Krams, Michael ^j   Luthman, Johan ^k   Potkin, Steven ^l   Gribkoff, Val ^m   Temple, Robert ^c   Wang, Yaning ^c   Carrillo, Maria C ⁿ   Stephenson, Diane ^f   Snyder, Heather ⁿ   Liu, Enchi ^o   Ware, Tony ^p   Mckew, John ^q   Fields, F Owen ^r   Bain, Lisa J ^s   Bens, Cynthia ^a   more..

^a Alliance for Aging Research   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f C Path Institute   (United States)

^g BROWN UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j Spring House   (United States)

^k EISAI INC   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m ELAN PHARMACEUTICALS   (United States)

ⁿ ALZHEIMER'S ASSOCIATION   (United States)

^o Janssen Pharmaceuticals   (United States)

^p ELI LILLY AND COMPANY   (United States)

^q NATIONAL INSTITUTES OF HEALTH   (United States)

^r PFIZER INC   (United States)

^s NONE   (United States)

more..

Author keywords

Alzheimer' disease; co development; collaboration; combination therapy; novel therapy

Indexed keywords

BETA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; DRUG COMBINATION; DRUG DESIGN; DRUG INDICATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; MODEL; SIMULATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; INFORMATION DISSEMINATION; THEORETICAL MODEL;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; INFORMATION DISSEMINATION; MODELS, THEORETICAL;

EID: 84923331513     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.996551     Document Type: Article

References (13)

1. Stephenson D, Perry D, Bens C, et al. Charting a path toward combination therapy for Alzheimer's disease. Available from: http://act-ad.org/wp-content/uploads/2014/05/Combination-therapy-for-AD-final-2.pdf 2012
2. Food and Drug Administration. Guidance for industry: enrichment strategies for clinical trials to support approval of human drug and biological products. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM332181.pdf 2012. [Last accessed 18 July 2013]
3. Food and Drug Administration. Draft guidance for industry. Alzheimer's disease: developing drugs for the treatment of early stage disease. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf 2013. [Last accessed 24 February 2013]
4. Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM236669.pdf 2010. [Last accessed 13 April 2014]
5. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28
6. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. N Engl J Med 2012;367:795-804
7. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer' s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-16
8. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012;336:1511-13
9. Kamboh MI, Demirci FY, Wang X, et al. Genome-wide association study of Alzheimer's disease. Trans Psychiatry 2012;2:e117
10. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013;153:707-20
11. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100
12. Bohrmann B, Caruso A, Tanghe A, et al. Combination therapy with Gantenerumab and BACE inhibitor accelerates amyloid lowering: New paradigm for treatment of Alzheimer's disease? In: The 11th International Conference on Alzheimer's & Parkinson's Diseases. Florence, Italy; 2013
13. TRAIN. The research acceleration and innovation network. Available from: http://train.fastercures.org/about/